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Abstract 
Objectives: To compare antimicrobial resistance in S. Typhi and S. Paratyphi A isolates from Pakistan. 
Methods: Blood samples were collected through > 175 laboratory collection points in major cities and towns across the country. 
The study included 3,671 S. Typhi and 1,475 S. Paratyphi A isolates (2001-2006). Multidrug resistance (MDR) was defined as 
resistance to first-line agents co-trimoxazole, chloramphenicol and ampicillin.  
Results: In total, 79.3% S. Typhi and 59.9% S. Paratyphi A were isolated from patients under 15 years of age. During the study 
period, the MDR rate increased in S. Typhi (34.2 to 48.5% p<0.001), but decreased in S. Paratyphi A (44.5 to 8.6% p<0.001). 
Quinolone resistance (MIC>1μg/ml) increased in both S. Typhi (1.6 to 64.1% p<0.001) and S. Paratyphi A (0 to 47% p<0.001). 
The increase in the proportion of strains showing high level quinolone resistance (MIC >4μg/ml) was greater in S. Paratyphi A 
when compared to S. Typhi. Resistance to first-line drugs was higher in those <15 years of age whereas quinolone resistance 
was higher in older patients. 
Conclusion: Differences between S. Typhi and S. Paratyphi A, in terms of evolution of resistance to first-line agents and to 
quinolones, are evident in this population. The rapid increase in quinolone resistance in S. Paratyphi A when compared to S. 
Typhi is concerning and requires further study. 
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Introduction 
Enteric fever is an acute, life-threatening, 
febrile illness caused by Salmonella enterica 
serovars Typhi, Paratyphi A, B and C, and is 
estimated to be responsible for 21 million illnesses 
and 200,000 deaths worldwide annually. It is 
further associated with significant economic 
consequences in developing countries [1]. The 
incidence rate of enteric fever in central and south 
Asia is estimated at more than 100 cases/100,000 
population per year with the highest burden of 
disease seen in children [1-5].  
Emergence of antimicrobial resistance, in 
particular multidrug resistance (MDR, resistance to 
chloramphenicol, ampicillin and co-trimoxazole) 
has greatly complicated disease management 
[6,7]. MDR S. Typhi first reported from Bangladesh 
in 1986 and from Pakistan in 1988 is currently 
endemic in South Asia [8-10]. Resistance in S. 
Paratyphi A is also emerging with a number of 
reports documenting prevalence of MDR S. 
Paratyphi A in this region [11-12]. 
Fluoroquinolones are regarded as the 
treatment of choice for enteric fever in adults. 
However, limited access to reliable clinical 
microbiology facilities and the ready availability 
and excessive use of low-cost substandard 
generics of fluoroquinolone has led to the 
emergence of fluoroquinolone resistance [13]. 
Clinical failures and inadequate responses to 
therapy are documented in patients infected with 
Salmonella strains with reduced susceptibility to 
fluoroquinolones (MIC > 0.125 ug/ml) [14-17]. 
Point mutations in chromosomal genes (gyrA, 
gyrB, parC, and parE) resulting in strains with 
reduced susceptibility as well as plasmid-encoded 
transferable resistance to fluoroquinolones have 
been reported from many countries [18-24].  
In Pakistan, the incidence of culture-proven 
enteric fever in children is estimated at 170 per 
100,000 of the population, whereas serology 
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based incidence is estimated at 710 per 100,000 
of the population [25]. Published reports suggest 
that the MDR rate amongst S. Typhi in the country 
decreased from 50% in 1995 to 20% in 2001 [6] 
while the rate in S. Paratyphi A increased from 
14% in 1996 to 44% in 2003 [26]. The aim of this 
study was to explore the current level of resistance 
to first-line agents and to quinolones amongst S. 
enterica serovars Typhi and Paratyphi A in 
Pakistan. We further aimed to study the change in 
antimicrobial resistance among these organisms 
over a six-year period, 2001-2006. 
 
Material and Methods 
S. enterica serovars Typhi and Paratyphi A 
isolated from blood cultures at the Aga Khan 
University’s Clinical Microbiology Laboratory were 
included in the study. Aga Khan University 
Hospital is a 550-bed, tertiary care centre located 
in Karachi, Pakistan. Its clinical laboratory receives 
samples from both in-patients and outpatients. The 
latter are collected through more than 175 
collection units located in all major cities and towns 
across the country.   
From January 2001 to December 2006, a total 
of 175,987 blood specimens were submitted to the 
clinical laboratory. Blood specimens were 
processed in the BACTEC system (Becton and 
Dickenson, USA). Positive blood samples were 
further cultured on sheep blood, chocolate and 
McConkey agar plates and incubated at 350-360C 
for 24  to 48 hours.   Suggestive non-lactose-
fermenter colonies were identified on the basis of 
standard biochemical tests using API20E and 
agglutination with Salmonella 09, Vi-specific and 
Hd antisera (S. Typhi), and with 02 and Ha 
antisera (S. Paratyphi A) (Difco laboratories). 
Antimicrobial susceptibility tests were performed 
using the Kirby Bauer disc diffusion method in 
accordance with the Clinical and Laboratory 
Standard Institute (CLSI) guidelines. Discs used 
included chloramphenicol (30µg), ampicillin 
(10µg), co-trimoxazole (1.25/23.75µg), nalidixic 
acid (30µg) and ofloxacin (5µg) [27]. Isolates 
resistant to chloramphenicol, ampicillin, and co-
trimoxazole were termed multi-drug resistant 
(MDR).  
Strains resistant to nalidixic acid were further 
confirmed as being fluoroquinolone resistant using 
minimum inhibitory concentration (MIC). MIC was 
determined by the standard agar dilution method 
using Muller Hinton agar as described in CLSI 
using Escherichia coli ATCC 25922 as a control 
27. A breakpoint of 0.125μg/ml was used as 
reduced susceptibility, and MIC of >1.0μg/ml as 
resistance to quinolones [28]. 
The data was extracted from the computerised 
hospital information system and transferred to 
SPSS 15.0 (SPSS Inc., Chicago, IL, USA) for 
statistical analysis. In descriptive analysis, means 
and standard deviations of the continuous 
variables and percentages of the categorical 
variables were computed. In inferential analysis, 
comparisons between resistant and sensitive 
strains by gender, age and location were 
conducted through chi square or Fisher’s exact 
test where appropriate. Year-wise trends were 
assessed through a chi square test for trend.  A p-
value of less than or equal to 5% was considered 
as statistically significant. 
 
Results 
A total of 3,671 Salmonella Typhi and 1,475 
Salmonella Paratyphi A strains isolated between 
2001 and 2006 were studied. In both S. Typhi and 
S. Paratyphi A, the majority of isolates were from 
children under the age of 15 years. However, as 
shown in Table 1, there was a greater 
representation of S. Typhi (79.3%) in the under 15 
group as compared to S. Paratyphi A (59.9%) 
p<0.001. No gender related difference in isolation 
rates of S. Typhi and S. Paratyphi A were 
detected. 
 
Table 1. Descriptive characteristics of patients positive 
for S. enterica serovar Typhi and Paratyphi A (2001-
2006). 
Characteristics S. Typhi n (%) 
S. para A 
n (%) p value 
Age in years 
<15 Years 
15 & above 
Missing information 
 
2910 (79.3) 
735 (20.0) 
26 (0.7) 
 
895 (59.9) 
592 (39.8) 
8 (0.5) 
 
<0.001* 
Gender 
Male 
Female 
Missing information 
 
2125 (57.9) 
1544 (42.0) 
2 (0.1) 
 
842 (56.3) 
651 (43.5) 
2 (0.1) 
 
0.316 
Total Lumber 3671 1495  
p-value calculated through chi squared test excluding the missing values, 
significance (* ) p<0.05. 
 
During the 6-year study period, resistance to 
co-trimoxazole, ampicillin and chloramphenicol 
showed a steady increase in S. Typhi (p<0.001). 
Conversely, the trend in S. Paratyphi A saw the 
MDR rate fall from 44.5% in 2001 to 8.6% in 2006 
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(p<0.001). During the same period, an increase in 
fluoroquinolone resistance was noted in both the 
groups (p<0.001) (Figures 1A & 1B).  
Figure 1. A (upper): Antimicrobial resistance; S. 
enterica serovar Typhi (2001-2006). B (lower): 
Antimicrobial resistance; S. enterica serovar Paratyphi 
A (2001-2006). 
Resistance is expressed as a percentage of the total strains isolated 
per year. The number of strains tested per year is depicted; (n value). 
Resistance to individual first-line agents as well as MDR increased in 
S. Typhi (p< 0.001), but decreased in S. Paratyphi (p<0.001). 
Resistance to Ofloxacin increased significantly in both organisms 
studied (p<0.001). 
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Comparison of the cumulative data (2001-
2006) for S. Typhi and S. Paratyphi A suggests a 
significant association between MDR and ofloxacin 
resistance in S. Typhi; 59.8% of MDR S. Typhi 
isolates were resistant to ofloxacin compared to 
only 16.5% of sensitive S. Typhi isolates 
(p<0.001). This trend, however, did not hold true 
for S. Paratyphi A where a negative association 
between MDR and quinolone resistance was 
apparent: 5.4% of MDR S. Paratyphi A isolates 
were resistant to ofloxacin as opposed to 19.6% of 
sensitive isolates (p<0.001). 
Analysis of MIC levels to ofloxacin in both the 
study organisms showed that the level of 
quinolone resistance in terms of MIC values was 
increasing in both S. Typhi and S. Paratyphi A 
over the 6-year study period. The increase in 
percentage of strains with ofloxacin MIC levels 
(>4mg/ml) was, however, markedly greater in S. 
Paratyphi A 0% (2001) to 28% (2006) as 
compared to S. Typhi 0% (2001 to 9%(2006) 
(Figures 2A & 2B). 
 
Figure 2. A: MIC to Ofloxacin; S. enterica serovar 
Typhi; B: MIC to Ofloxacin; S. enterica serovar 
Paratyphi A. 
Minimum Inhibitory Concentration (MIC) values for S. Typhi and 
paratyphi A that were naladixic acid resistant on initial screening 
(2001-2006).  
The number of strains tested per year is shown (n value).  
MIC values (range 0.125 to >4.0 μg/ml) are as follows as depicted in 
figure legend. 
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Isolates from younger patients (<15years) were 
more likely to be resistant to ampicillin (p=0.017) 
and co-trimoxazole (p=0.016) in the case of S. 
Typhi, and to ampicillin (p=0.002), 
chloramphenicol (p<0.001) and co-trimoxazole 
(p<0.001) in cases of S. Paratyphi A. Resistance 
to fluoroquinolones in both organisms, however, 
was more likely in the older age groups (p<0.001) 
(Table 2). 
 
Table 2. Distribution of antibiotic sensitivity in S. 
enterica serovars Typhi and Paratyphi isolates 
according to age (2001-2006). 
Feature Age (y) n 
Amp Chloram Cotrim MDR Oflox 
%-R %-R %-R %-R %-R 
ST 
(n:3671) 
<15 
≥15 
2909 
735 
44.2 
39.4 
40.5 
38.2 
44.8 
39.9 
39.3 
36.1 
31.2 
41.4 
P 0.017* 0.270 0.016* 0.107 <0.001* 
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SPT 
(n:1495) 
<15 
≥15 
895 
592 
27.9 
20.7 
29.5 
21.3 
29.9 
20.3 
26.6 
19.1 
13.5 
20.8 
P 0.002* <0.001* <0.001* 0.001* <0.001* 
ST= S. Typhi; SPT= S. Paraty-phi A; Amp = Ampicillin; Chloram = Chloramphenicol; Cotrim = 
Co-trimoxzole; MDR = Multi drug resistant = Resistant to Ampicillin, Chloramphenicol and 
Co-trimoxazole; Oflox = Ofloxacin. Age analysis was not conducted for 27 S. Typhi and 8 S. 
Paratyphi A patients due to missing information. p-value calculated through chi squared test 
excluding the missing values, significance (*) p<0.05. 
 
Discussion 
We compared resistance trends of S. enterica 
serovars Typhi and S. Paratyphi A isolated 
between 2001 and 2006. During that period, the 
isolation rate of S. Typhi was significantly greater 
than that of S. Paratyphi A. This finding is in 
agreement with published data indicating typhoid 
fever as more prevalent than paratyphoid in this 
region [12,25,29]. 
A higher frequency of both Typhi and Paratyphi 
A in the younger age group, reported in this study, 
also concurs with published literature showing a 
greater burden of enteric fever in children as 
compared to adults [2-5,25].  Comparison of strain 
distribution between adults and children showed 
that children bore 79.3% of the S. Typhi burden as 
compared to 59.9% of S. Paratyphi A. This 
difference, while similar to that reported from India 
[29,30], is difficult to explain. It is possible to 
hypothesise that, when compared to S. Typhi, the 
lower overall prevalence of S. Paratyphi A in the 
community reduces chances of exposure and 
hence likelihood of disease in the younger age 
group. 
The increase in resistance amongst S. Typhi to 
the first-line agents co-trimoxazole, 
chloramphenicol and ampicillin is concerning and 
likely to reflect persistence and dissemination of 
resistant S. Typhi strains within our community. In 
contrast, the decrease in resistance to the first-line 
agents in S. Paratyphi A is encouraging but 
surprising in view of earlier reports of upward 
resistance trends among S. Paratyphi A in the 
country [26]. A similar decrease in resistance 
among S. Paratyphi A has also been documented 
in a recent report from India [31]. It is possible to 
link this downward trend in resistance among S. 
Paratyphi A to the fact that third-generation 
cephalosporins have, to a large extent, replaced 
co-trimoxazole, chloramphenicol and ampicillin as 
the treatment of choice for enteric fever in children. 
Our data further suggests, however, that the 
resistant strains of S. Paratyphi A have not 
succeeded in establishing themselves in the 
community. It has been suggested that 
antimicrobial resistance in Salmonella may be 
associated with a fitness cost [32]. Whether the 
resistance in S. Paratyphi A has an associated 
fitness cost needs to be investigated. S. Paratyphi 
A has been shown to harbour resistance plasmids 
[33]. It is possible that in the absence of antibiotic 
pressure, these plasmids are not retained but may 
be re-acquired when antibiotic pressure is 
reimposed [34]. 
Fluoroquinolone resistance in S. Typhi as well 
as in S. Paratyphi A increased during the 6-year 
study period, both in terms of frequency and MIC 
levels. Fluoroquinolones available over the counter 
in the country are used to treat a number of 
infections including urinary and respiratory tract 
infections. Resistance is most likely a 
consequence of their widespread use in the 
community. Such increase in resistance to 
fluoroquinolones amongst S. enterica has been 
widely reported [14-17]. However, the sharp rise in 
S. Paratyphi A MIC levels as compared to S. Typhi 
is concerning. This observation, suggesting that S. 
Paratyphi A is more prone to developing 
fluoroquinolone resistance, requires further 
exploration.  
The difference in resistance between the 
younger and older age groups noted in this study 
is difficult to explain. Moreover, our finding is in 
contrast to data from Delhi reporting no difference 
in antimicrobial resistance across age groups in 
their patients [30]. Our data of higher resistance to 
co-trimoxazole, chloramphenicol and ampicillin 
among isolates from the younger age group and 
greater fluoroquinolone resistance in strains from 
older patients is consistent with antimicrobial 
usage in these two patient groups. The difference 
between our study and that from Delhi may well be 
related to the fact that, in the Delhi study, patients 
with history of antimicrobial therapy were 
excluded. The finding of age-related difference in 
antimicrobial resistance is also surprising given 
that risk factors for typhoid reportedly include a 
recent case in the family [35,36]. However, typhoid 
fever in endemic settings has been linked with 
high-dose exposure from multiple sources and 
therefore the possibility of an extra-familial source 
cannot be excluded in such cases [37]. Prior 
antimicrobial usage is reported to be a risk factor 
for typhoid [37,38]. However, the impact of such 
antimicrobials on the resistance pattern of the 
infecting organisms needs to be considered. The 
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role of commensal flora within host intestinal flora 
harbouring resistance plasmids and contributing to 
development of resistance S. enterica serovars is 
also a distinct possibility requiring exploration.  
In conclusion, our data suggests that there 
appear to be differences between S. enterica 
serovar Typhi and S. Paratyphi A in terms of 
resistance trends to first-line agents, co-
trimoxazole, chloramphenicol and ampicillin. 
These differences need to be explored further. 
Increasing resistance to fluoroquinolones is 
alarming and of particular concern is the rapid rise 
in MIC levels among S. Paratyphi A. Similarly, 
differences in resistance patterns between 
younger and older age groups need to be further 
studied. 
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